Key Highlights

  • NIOX Group Plc (LSE:NIOX) came within a whisker of leaving the London market last year.
  • Keensight Capital's indicative 81p-a-share approach in March 2025 won a "minded to recommend" from the board, only for the Private Equity firm to walk away in April citing macroeconomic conditions.
  • NIOX's most recent material announcement was its trading update for the six months to 30 June 2026, published on 28 July 2026.
  • Group Revenue slipped 4.8% to £24.0m from £25.2m a year earlier.

NIOX Group Plc (LSE: NIOX) came within a whisker of leaving the London market last year. Keensight Capital's indicative 81p-a-share approach in March 2025 won a "minded to recommend" from the board, only for the private equity firm to walk away in April citing macroeconomic conditions. Today the AIM-quoted asthma diagnostics specialist remains independent, debt-free and cash-generative, yet its shares traded at 67.6p on 2 September 2026, well below the price a bidder once judged acceptable. The question is whether 2026 is the year the market re-engages. A next-generation device, NIOX PRO, has just launched, a 45% reimbursement uplift in Japan has taken effect, and management has flagged a Capital return in the second half. Against that, the 28 July trading update showed first-half revenue falling as lumpy research sales dropped sharply.

First-half 2026 trading update: clinical growth masked by research slump

NIOX's most recent material announcement was its trading update for the six months to 30 June 2026, published on 28 July 2026. Group revenue slipped 4.8% to £24.0m from £25.2m a year earlier. The clinical Business grew 3% to £20.6m, but the research segment, which supplies devices to pharmaceutical Clinical Trials and had surged 77% in 2025 on the back of COPD studies, fell 34.6% to £3.4m. Gross Margin edged up to around 71% from 70% on a smaller weighting of lower-margin research device sales. Operating expenditure rose to £8.8m from £8.6m, leaving adjusted EBITDA of £8.3m, down 9.8% from £9.2m. Net cash was £16.8m at 30 June 2026, down from £19.9m at December 2025 after a £6.5m final dividend. Crucially, the company still expects to meet full-year consensus of £50.5m revenue and £17.5m adjusted EBITDA, implying a materially stronger second half. Chief executive Jonathan Emms said customer feedback on NIOX PRO had been "extremely encouraging" and that the second half would be "stronger than the first, supported by the commercial rollout of NIOX PRO and Japan pricing implementation". The update also listed milestones: CE Mark and UK MHRA approval for NIOX PRO, with US and Japanese clearances expected in the second half; a 10-year exclusive sensor Supply agreement; a US field sales team fully deployed in March 2026; and a master services agreement with a leading contract research organisation. The board also intends to return excess capital to shareholders in the second half of 2026.

What NIOX does: the global leader in FeNO testing

NIOX develops, manufactures and sells devices that measure fractional exhaled nitric oxide (FeNO), a biomarker of airway inflammation used to diagnose and manage asthma. It pioneered the test in 1998 and describes itself as the global leader in the field. Its flagship NIOX VERO analyser is used in primary care, hospitals and pharmacies, and increasingly to guide biologic asthma therapies. The model is razor-and-blade: devices are sold or placed, and Recurring Revenue comes from single-use sensors with each test performed, giving the clinical segment a high-margin, repeatable character. The research segment supplies devices to pharmaceutical trials and is lucrative but volatile, depending on the timing of trial starts. NIOX reports across the Americas, EMEA and APAC. In 2025, China grew 14%, the UK 5% and the United States 7%. According to the March 2026 final results, around 93% of insured lives in the US now have FeNO coverage, and Japan's reimbursement Tariff rose from JPY 1,000 to JPY 1,450 per test from 1 June 2026.

FY2025 results: record revenue, rising margins and a bigger dividend

NIOX's most recent audited figures cover the year to 31 December 2025, published on 24 March 2026. Revenue rose 17% to £48.7m (15% at constant currency), beating consensus of £47.2m. Clinical revenue grew 7% to £38.6m while research revenue jumped 77% to £10.1m. Gross margin fell to 69% from 72% because of the device-heavy research mix. Adjusted EBITDA increased 21% to £16.7m, ahead of the £15.9m consensus, operating profit rose to £10.7m from £7.7m and profit before tax reached £11.2m against £7.8m in 2024. Basic EPS rose to 1.69p from 0.88p, with adjusted basic EPS of 4.03p versus 3.23p. Year-end cash was £19.9m, up from £10.9m, with no debt. The board recommended a final Dividend of 1.55p per share, up from 1.25p, and targets returning at least 80% of free Cash Flow to shareholders over the medium term. Administrative expenses included a £0.3m one-off cost relating to the withdrawn Keensight bid. Chairman Ian Johnson called 2025 "another excellent year for NIOX".

What could drive the shares next?

The most immediate catalyst is the interim results for the six months to June 2026; last year's were published on 30 September. Investors will look for evidence that NIOX PRO is converting feedback into orders and that the second-half weighting needed to reach £50.5m of revenue is on track. Regulatory decisions matter too. US and Japanese clearances for NIOX PRO are expected in the second half of 2026 and would open the two largest FeNO markets to the new device. In Japan, the higher reimbursement rate should lift revenue per test from June onwards, while the productivity of the newly deployed US sales team will be closely watched. The promised second-half capital return is a tangible near-term event. With £16.8m of net cash and a policy of distributing at least 80% of free cash flow, shareholders may see a Special Dividend or a tender offer, as in October 2024.

Risks investors should watch

The research segment's 35% first-half decline illustrates its lumpiness; further weakness would leave the group reliant on a strong clinical finish. Guidance is heavily second-half weighted, so any delay to NIOX PRO approvals in the US or Japan, or a slower commercial ramp, would put consensus at risk. NIOX depends on a single product family and a single biomarker. Competing FeNO devices, or changes in clinical guidelines and reimbursement, could erode pricing. Development spend on NIOX PRO, MyNO and NIOX Cloud is rising, with MyNO not expected to generate near-term revenue. Reporting in sterling while earning most revenue overseas, currency swings also affect reported growth. The failed 2025 sale process also carries a lesson: a bidder's interest is not a floor. Keensight withdrew despite Due Diligence access and a board willing to recommend 81p, and the shares now trade below that level.

Outlook

NIOX enters the autumn with clear markers. The interim results should show whether NIOX PRO and Japanese pricing are delivering the promised second-half acceleration and whether the research pipeline is refilling. US and Japanese approvals for the new device, and the size and form of the capital return, will follow. The fundamentals are straightforward: a market-leading niche product, recurring consumable revenue, gross margins around 70%, no Debt and a record of beating consensus in 2025. Whether the shares deserve the label "overlooked" will depend on execution against a demanding second-half target, and on how the market values a small-cap MedTech that a private equity buyer once priced at 81p per share.